Inogen (INGN) has been quite an intriguing stock in recent years. The producer of innovative respiratory products saw its share price practically explode from $30 to $300 between 2016 and late 2018. Now, two years later, we are back to $30 as heightened expectations have not turned into reality.
With the company not bleeding money, actually having a strong net cash position, and attention and interest for respiratory conditions on the rise amidst Covid-19, it certainly feels like time to check on the current prospects of the investment case.
The Thesis
My last